These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 29145151)

  • 1. Vildagliptin loaded triangular DNA nanospheres coated with eudragit for oral delivery and better glycemic control in type 2 diabetes mellitus.
    Baig MMFA; Khan S; Naeem MA; Khan GJ; Ansari MT
    Biomed Pharmacother; 2018 Jan; 97():1250-1258. PubMed ID: 29145151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes.
    Vardarli I; Nauck MA; Köthe LD; Deacon CF; Holst JJ; Schweizer A; Foley JE
    J Clin Endocrinol Metab; 2011 Apr; 96(4):945-54. PubMed ID: 21239518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and evaluation of DNA nano-cubes as a core material protected by the alginate coating for oral administration of anti-diabetic drug.
    Baig MMFA; Abbas M; Naveed M; Kassim SA; Khan GJ; Sohail M; Ullah S; Hasnat M; Shah K; Ansari MT
    J Food Drug Anal; 2019 Jul; 27(3):805-814. PubMed ID: 31324296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
    Ishibashi K; Hara A; Fujitani Y; Uchida T; Komiya K; Tamaki M; Abe H; Ogihara T; Kanazawa A; Kawamori R; Watada H
    Biochem Biophys Res Commun; 2013 Nov; 440(4):570-5. PubMed ID: 24103756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes.
    Miyagawa K; Kondo T; Goto R; Matsuyama R; Ono K; Kitano S; Kawasaki S; Igata M; Kawashima J; Matsumura T; Motoshima H; Araki E
    Cardiovasc Diabetol; 2013 Nov; 12():160. PubMed ID: 24188631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.
    Serra D; He YL; Bullock J; Riviere GJ; Balez S; Schwartz S; Wang Y; Ligueros-Saylan M; Jarugula V; Dole WP
    Int J Clin Pharmacol Ther; 2008 Jul; 46(7):349-64. PubMed ID: 18793589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
    Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
    Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet.
    Halimi S; Schweizer A; Minic B; Foley J; Dejager S
    Vasc Health Risk Manag; 2008; 4(3):481-92. PubMed ID: 18827867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.
    He YL; Valencia J; Zhang Y; Schwartz SL; Ligueros-Saylan M; Foley J; Dole WP
    Br J Clin Pharmacol; 2010 Jul; 70(1):34-42. PubMed ID: 20642545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small Intestinal Glucose Delivery Affects the Lowering of Blood Glucose by Acute Vildagliptin in Type 2 Diabetes.
    Wu T; Zhang X; Trahair LG; Bound MJ; Little TJ; Deacon CF; Horowitz M; Jones KL; Rayner CK
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4769-4778. PubMed ID: 27598511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vildagliptin (Galvus) and fixed combination vildagliptine-metformin (Eucreas) in the treatment of type 2 diabetes].
    Scheen AJ; Paquot N
    Rev Med Liege; 2009 Mar; 64(3):161-7. PubMed ID: 19418936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2 diabetes.
    Vianna AGD; Lacerda CS; Pechmann LM; Polesel MG; Marino EC; Faria-Neto JR
    Diabetes Res Clin Pract; 2018 May; 139():357-365. PubMed ID: 29596951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl peptidase 4 inhibitor reduces intimal hyperplasia in rabbit autologous jugular vein graft under poor distal runoff.
    Koyama A; Komori K; Otsuka R; Kajikuri J; Itoh T
    J Vasc Surg; 2016 May; 63(5):1360-70. PubMed ID: 25656593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vildagliptin: a review of its use in the management of type 2 diabetes mellitus.
    Croxtall JD; Keam SJ
    Drugs; 2008; 68(16):2387-409. PubMed ID: 18973400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.
    Derosa G; Ragonesi PD; Carbone A; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P
    Diabetes Technol Ther; 2012 Jun; 14(6):475-84. PubMed ID: 22512264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats.
    Ávila Dde L; Araújo GR; Silva M; Miranda PH; Diniz MF; Pedrosa ML; Silva ME; de Lima WG; Costa DC
    Arch Med Res; 2013 Apr; 44(3):194-202. PubMed ID: 23523961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats.
    Refaat R; Sakr A; Salama M; El Sarha A
    Drug Dev Res; 2016 Sep; 77(6):300-9. PubMed ID: 27520857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA scaffold nanoparticles coated with HPMC/EC for oral delivery.
    Baig MMFA; Naveed M; Abbas M; Chunxia W; Ullah S; Hasnat M; Shad A; Sohail M; Khan GJ; Ansari MT
    Int J Pharm; 2019 May; 562():321-332. PubMed ID: 30928213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3).
    Kitao N; Miyoshi H; Furumoto T; Ono K; Nomoto H; Miya A; Yamamoto C; Inoue A; Tsuchida K; Manda N; Kurihara Y; Aoki S; Nakamura A; Atsumi T;
    Cardiovasc Diabetol; 2017 Oct; 16(1):125. PubMed ID: 29017497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus.
    Forst T; Dworak M; Berndt-Zipfel C; Löffler A; Klamp I; Mitry M; Pfützner A
    Diabetes Obes Metab; 2013 Jun; 15(6):576-9. PubMed ID: 23384119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.